- Open Access
WTX R353X mutation in a family with osteopathia striata and cranial sclerosis (OS-CS): case report and literature review of the disease clinical, genetic and radiological features
© Zicari et al.; licensee BioMed Central Ltd. 2012
- Received: 25 March 2012
- Accepted: 20 June 2012
- Published: 20 June 2012
Osteopathia striata with cranial sclerosis (OS-CS) or Horan-Beighton syndrome is a rare X-linked dominant inherited bone dysplasia, characterized by longitudinal striations of long bones and cranial sclerosis. Patients can be asymptomatic or present with typical facial dysmorphism, sensory defects, internal organs anomalies, growth and mental retardation, depending on the severity of the disease. WTX gene (Xq11) has been recently identified as the disease causing gene. Aim of this article is to present the case of a 6 year old girl initially evaluated for bilateral hearing loss. Patient’s head CT scan pointed out sclerosis of skull base and mastoid cells, and abnormal middle-ear ossification. Clinical examination of the patient and her mother were suspicious for OS-CS. The diagnosis was confirmed by X-rays examination showing typical longitudinal striation. Genetic analysis allowed the identification of maternally transmitted heterozygous nonsense c.1057C>T (p.R353X) WTX gene mutation. We also provide a systematic review of currently available knowledge about clinical, radiologic and genetic features typical of the OS-CS.
- Osteopathia striata
- Cranial sclerosis
- Horan-Beighton syndrome
- Bone dysplasia
Osteopathia striata with cranial sclerosis (OS-CS; OMIM#300373) is a rare, X-linked dominant inherited skeletal dysplasia (prevalence 0.1/1 million people ), part of sclerosing bone dysplasias [2–4], a group of disorders characterized by abnormally dense bones as a result of the prevalence of bone formation by osteoblasts over bone reabsorption by osteoclasts. Striated methaphyses were firstly described by Voorhoeve in 1924 ; thirty years later, Hurt  reported a case of association with cranial sclerosis. To date, about one hundred cases have been reported. Age at diagnosis and clinical presentation is highly variable, ranging from asymptomatic to neonatal lethal cases. Skull thickening, responsible for characteristic facies, and linear striations in the metaphyseal region of the long bones and pelvis represent disease main features, the latter representing a key feature for differential diagnosis [2–4]. Nervous and internal organs defects can be associated. Causing-disease mutations of WTX (Wilms Tumor in the X; also called FAM123B and AMER1) have recently been identified.
Aim of this paper is to present the first case of OS-CS with maternal transmission of a heterozygous 1057C>T WTX gene mutation, and to summarize currently available knowledge on OS-CS clinical, radiological and genetic features.
Patient’s mother presented very similar facial features; particularly, she had mild hypertelorism with epicanthal folds, a slightly depressed nasal bridge and hypoplastic maxillae (Figure 2b). X-rays examination of lower limbs revealed longitudinal sclerotic striations in the metaphysis of femurs and tibias.
Molecular analysis of WTX
The DNA from peripheral blood leukocytes of the patient and of her mother was extracted using QIAamp DNA Blood Mini kit (QIAGEN, Milan, Italy). Sequencing of the entire coding region of WTX was performed as previously described  and allowed the identification of the heterozygous nonsense mutation c.1057C>T, leading to a truncated protein (p.R353X) (Figure 3b). This mutation had been previously reported as a de novo mutation only in two sporadic cases .
A systematic literature review was performed using PubMed database entering the words “osteopathia striata”, “cranial sclerosis”, “Horan-Beighton syndrome”, “WTX gene”. Articles written in English and published since 1953 were included (Additional file 1).
The clinical presentation is highly variable even within the same family. Patients can be asymptomatic and accidentally diagnosed during X-rays examinations, or present with disabling physical anomalies, sometimes leading to premature death. Age at diagnosis varies from neonatal period to the 5th decade .
Skull thickening (cranial sclerosis) is the most typical and early feature [1, 6, 8, 10–37] (85%), often presenting before longitudinal bone striations, and typically affects cranial vault, base and some facial bones, leading to sinuses obliteration and reduction of mastoid pneumatization [1, 10, 12–14, 19, 21, 26, 33, 34] (sometimes responsible for failure to thrive). Facial dysmorphisms include macrocephaly (43%) [2, 11–17, 19, 20, 27–32, 34, 36–39], frontal and occipital bossing (32%) [2, 11–15, 17, 19–21, 30–33, 36], mandible overgrowth with protuberance of the jaw and dental malocclusion (12%) [2, 11, 14, 23] (giving a leonine appearance), ocular hypertelorism [6, 8, 10, 14, 19, 20, 23, 27, 29–31, 38–40], down-slanting palpebral fissures [19, 28, 31], low set broad nasal bridge (29%) [1, 2, 6, 8, 12, 14, 15, 17, 18, 20, 23, 30–32, 37, 38, 41, 42], narrow high-arched or cleft palate (Pierre Robin’s triad) (12%) [2, 6, 8, 14–16, 19, 21, 30, 31, 35] and low set dysplastic ears (9%) [6, 12, 19, 20, 29–31, 33, 39, 42].
Longitudinal striations can be typically demonstrated in long bones (73%), less frequently in pelvis (fan-like striations) (19%)[1, 2, 6, 8, 10–15, 17–22, 24–26, 28–32, 34–38, 40, 42], vertebrae and ribs, and can be associated to diffuse osteosclerosis (35%) [3, 21, 25, 26, 28–32, 34, 36, 43]. Patients can also present thoracic and vertebral anomalies (2%) [8, 13, 14, 19–21, 28–32, 35, 42], digital flection contractures, phalangeal duplication, syndactyly, short or absent fibula, club feet (3%) [8, 10, 14, 16, 17, 20, 28–31, 35, 36, 38, 40].
Hearing loss (conductive or mixed type) is the most common neurological manifestation (46%) [1, 2, 6, 8, 11, 14, 16, 17, 19–23, 27, 28, 30, 31, 33–38, 40, 41, 43], resulting from narrowing of external auditory canal, impaired mobility of middle ear ossicles, damage to the inner ear or auditory nerve entrapment. Narrowed nerves’ canals and foramina are responsible for nerve encroachment and palsies [1, 14, 17, 19, 20, 30, 31, 37–39, 41, 42]. A minority of patients presents intellectual impairment associated to defects of the central nervous system (i.e. ventricular dilatation, abnormal gyration, agenesis of corpus callosum) and developmental delay (overall, 20%) [2, 8, 14, 17, 19, 20, 29–33, 35, 37–40, 43].
Internal organs defects
Patients can finally present congenital heart defects (i.e. patent ductus arteriosus, atrial and ventricular septal defects, valvular and conductive defects) (11%) [8, 11, 12, 14, 20, 27, 29–31, 35, 37, 41, 43], respiratory (i.e. laryngotracheomalacia, respiratory distress, nasal obstruction, recurrent bronchitis) (13.5%) [6, 13, 17, 19–21, 23, 28, 30, 31, 37–39], gastrointestinal (i.e. malrotation, omphalocele, Hirschsprung disease, imperforate anus) (12%) [8, 12, 13, 21, 23, 29–32, 35] and urogenital (i.e. cryptorchidism, micropenis, duplicated ureter) (10%) [8, 20, 29–31, 44] anomalies.
OS-CS has been classically considered an autosomal dominant condition with high penetrance and variable intra- and interfamilial expressivity [4, 9, 12, 15–17, 21, 43] until the recent identification of mutated WTX (Wilms Tumor in the X; also called FAM123B and AMER1) within proximal Xq11.2 in affected families . WTX can be spliced: the full length form encodes for a 1135 aminoacid protein, WTXs1, which possesses three binding sites for APC (adenomatous polyposis coli), a β-catenin- (C-terminal), a WT1- and a PIP2 (phosphatidylinositol 4.5 bisphosphate, at N-terminus)- binding site; and a shorter isoform, WTXs2 (missing aminoacids 50-326) keeps the first APC- binding domain [45–47]. WTX interacts with AXIN1, APC and β-TrCP2, promoting the ubiquitination and proteasomal degradation of β-catenin (binding site located at the C-terminal)  and the inhibition of the WNT signaling pathway . Both isoforms can bind β-catenin but, while WTXs1 has a predominant plasma membrane and cytoplasmic localization, WTXs2 (missing PIP2-binding site) is retained in the nucleus, suggesting the importance of cellular localization for protein function [8, 45, 47]. In absence of WTX, β-catenin accumulates in the nucleus and works as a transcriptional co-activator . Because WNT signal pathway is involved in various embryonic development (including commitment of mesenchymal progenitor cells and differentiation of osteoblast precursors ) and homeostasis of adult tissues , its enhanced activity, due to mutations of the suppressor WTX, is responsible for the different alterations and phenotypes observed in patients.
Hemizygous males usually are more severely affected than heterozygous females and present, other than more marked bone sclerosis, craniofacial abnormalities, gross structural malformations of bones and internal organs, and significant pre- and postnatal lethality . More recently, families with mildly affected males, characterized by longer longevity, mild short stature and neurodevelopmental disability, have been reported [18, 26, 35, 37, 43], although the phenotype has not been completely defined yet . A genotype-phenotype correlation, where patient with 5′ WTX mutations were more severely affected than patients with 3′ WTX mutations was proposed by Jenkins , but not confirmed by Perdu [30, 31] who described mildly affected patients with 5′ WTX mutation, indicating a variable correlation between position of mutation and the severity of the phenotype. Because 5′ mutations produce a truncated, non-functioning protein, mild phenotype could be the result of a compensatory activity of WTXs2, even if the exact molecular mechanisms remain unidentified [20, 46].
Metaphyseal striations can be seen only in females, and males with mosaic mutations [18, 37, 40]. A reasonable explanation is the differential lionization of osteoblasts for which, similarly to what happens in heterozygous females presenting with random X chromosome inactivation patterns, only a certain amount of osteoblasts is affected .
Somatic mutations and deletions of WTX have been reported in 6 to 30% of patients with Wilms tumors (WT), a kidney cancer typical of childhood, arising from multipotent mesenchymal kidney precursors [7, 44, 46, 49]; WTX has later been identified as OS-CS disease-causing-gene, both in familial and sporadic cases. Despite germline mutations in tumor suppressor gene confer an elevated risk for cancer, and patients with WT and OS-CS share a similar distribution of WTX mutations, OS-CS is not associated with an increased neoplastic risk . Moisan et al.  demonstrated in a conditional Wtx knockout mouse model the presence of malformations affecting organs derived from mesenchymal progenitors, including kidneys, adipose tissue, heart, spleen and bones, very similar to those reported in children with OS-CS. At the same time, some mice developed bilateral multifocal expansion of renal precursors, but not Wilms tumors, suggesting a complex role of WTX in kidney development, whose alteration can lead to tissue agenesis or overgrowth. Mutations associated to WTX-interacting proteins have also been advocated to explain tumor development .
OS-CS is a rare bone dysplasia, characterized by longitudinal long bone striations and cranial sclerosis. Typical facial dysmorphism, sensory defects, internal organs anomalies, growth and mental retardation can be associated, helping the physician in the diagnosis, otherwise very challenging in asymptomatic cases. Although rare, because of the severe health impairment that the associated malformations could lead to, and the family inheritance of the disease, OS-CS should be considered in patients affected by or with a family history of deafness, especially if it is associated to facial dysmorphism, sensory defects, internal organ malformations or developmental delay. When OS-CS is suspected, radiographic imaging such as x-rays of the skull and long bones and cranial CT, are required to confirm the presence of the typical bone lesions. Opthalmological examination can be useful to identify optic nerve defects, as for abdominal and heart ultrasound for the detection of internal organs malformations, respectively. Family members should also be investigated. Genetic analyses for WTX mutations in the patient and in the patient’s family could be useful for genetic counseling, even if it should be kept in mind that no clear correlation between genotype and phenotype exists.
Written informed consent was provided by parents on behalf of the patient for the publication of this case report and any accompanying images.
This work was supported by grants from the Associazione Bianca Garavaglia, Busto Arsizio, Varese, Italy, and Italian Association for Cancer Research (AIRC) to DP. We are further thankful to Professor Mario Roggini and Michele Sardella for excellent technical assistance.
- Berenholz L, Lippy W, Harrell M: Conductive hearing loss in osteopathia striata-cranial sclerosis. Otolaryngol Head Neck Surg. 2002, 127 (1): 124-126.View ArticlePubMedGoogle Scholar
- Bass HN, Weiner JR, Goldman A, Smith LE, Sparkes RS, Crandall BF: Osteopathia striata syndrome. Clinical, genetic and radiologic considerations. Clin Pediatr (Phila). 1980, 19 (5): 369-373.View ArticleGoogle Scholar
- Hurt RL: Osteopathia striata-Voorhoeve’s disease; report of a case presenting the features of osteopathia striata and osteopetrosis. J Bone Joint Surg Br. 1953, 35-B (1): 89-96.PubMedGoogle Scholar
- Nakamura K, Nakada Y, Nakada D: Unclassified sclerosing bone dysplasia with osteopathia striata, cranial sclerosis, metaphyseal undermodeling, and bone fragility. Am J Med Genet. 1998, 76 (5): 389-394.View ArticlePubMedGoogle Scholar
- Voorhoeve N: L’image radiologique non encore decrite d’une anomalie du squelette. Acta Radiol. 1924, 3: 407-411.View ArticleGoogle Scholar
- Magliulo G, Parrotto D, Zicari AM, Zappala D, Lo Mele L, Primicerio P, Marini L: Osteopathia striata-cranial sclerosis: otorhinolaryngologic clinical presentation and radiologic findings. Am J Otolaryngol. 2007, 28 (1): 59-63.View ArticlePubMedGoogle Scholar
- Perotti D, Gamba B, Sardella M, Spreafico F, Terenziani M, Collini P, Pession A, Nantron M, Fossati-Bellani F, Radice P: Functional inactivation of the WTX gene is not a frequent event in Wilms’ tumors. Oncogene. 2008, 27 (33): 4625-4632.View ArticlePubMedGoogle Scholar
- Jenkins ZA, van Kogelenberg M, Morgan T, Jeffs A, Fukuzawa R, Pearl E, Thaller C, Hing AV, Porteous ME, Garcia-Miñaur S, Bohring A, Lacombe D, Stewart F, Fiskerstrand T, Bindoff L, Berland S, Adès LC, Tchan M, David A, Wilson LC, Hennekam RC, Donnai D, Mansour S, Cormier-Daire V, Robertson SP: Germline mutations in WTX cause a sclerosing skeletal dysplasia but do not predispose to tumorigenesis. Nat Genet. 2009, 41 (1): 95-100.View ArticlePubMedGoogle Scholar
- Winter RM, Crawfurd M, Meire HB, Mitchell N: Osteopathia striata with cranial sclerosis: highly variable expression within a family including cleft palate in two neonatal cases. Clin Genet. 1980, 18 (6): 462-474.View ArticlePubMedGoogle Scholar
- Lazar CM, Braunstein EM, Econs MJ: Clinical vignette: osteopathia striata with cranial sclerosis. J Bone Miner Res. 1999, 14 (1): 152-153.View ArticlePubMedGoogle Scholar
- Bueno AL, Ramos FJ, Bueno O, Olivares JL, Bello ML, Bueno M: Severe malformations in males from families with osteopathia striata with cranial sclerosis. Clin Genet. 1998, 54 (5): 400-405.View ArticlePubMedGoogle Scholar
- Bar-Oz B, Mogle P, Ben-Neriah Z, Sheffer R, Arad I: Duodenal web in the syndrome of osteopathia striata with cranial sclerosis. Clin Genet. 1996, 49 (6): 329-330.View ArticlePubMedGoogle Scholar
- Bloor DU: A case of osteopathia striata. J Bone Joint Surg Br. 1954, 36-B (2): 261-265.PubMedGoogle Scholar
- Clementi M, Bellato S, Rossetti A, Mammi I, Tenconi R: Is visual field reduction a component manifestation of osteopathia striata with cranial sclerosis?. Am J Med Genet. 1993, 46 (6): 724-726.View ArticlePubMedGoogle Scholar
- Cortina H, Vallcanera A, Vidal J: Familial osteopathia striata with cranial condensation. Pediatr Radiol. 1981, 11 (2): 87-90.View ArticlePubMedGoogle Scholar
- Currarino G, Friedman JM: Severe craniofacial sclerosis with multiple anomalies in a boy and his mother. Pediatr Radiol. 1986, 16 (6): 441-447.View ArticlePubMedGoogle Scholar
- De Keyser J, Bruyland M, De Greve J, Leemans J, Potvliege R, Six R, Ebinger G: Osteopathia striata with cranial sclerosis. Report of a case and review of the literature. Clin Neurol Neurosurg. 1983, 85 (1): 41-48.View ArticlePubMedGoogle Scholar
- Deniz FE, Koseoglu RD: Osteopathia striata with cranial sclerosis and lumbar spinal stenosis. Acta Neurochir (Wien). 2007, 149 (8): 811-815.View ArticleGoogle Scholar
- Gay BB, Elsas LJ, Wyly JB, Pasquali M: Osteopathia striata with cranial sclerosis. Pediatr Radiol. 1994, 24 (1): 56-60.View ArticlePubMedGoogle Scholar
- Holman SK, Daniel P, Jenkins ZA, Herron RL, Morgan T, Savarirayan R, Chow CW, Bohring A, Mosel A, Lacombe D, Steiner B, Schmitt-Mechelke T, Schroter B, Raas-Rothschild A, Miñaur SG, Porteous M, Parker M, Quarrell O, Tapon D, Cormier-Daire V, Mansour S, Nash R, Bindoff LA, Fiskerstrand T, Robertson SP: The male phenotype in osteopathia striata congenita with cranial sclerosis. Am J Med Genet A. 2011, 155A (10): 2397-2408.View ArticlePubMedGoogle Scholar
- Horan FT, Beighton PH: Osteopathia striata with cranial sclerosis. An autosomal dominant entity. Clin Genet. 1978, 13 (2): 201-206.View ArticlePubMedGoogle Scholar
- Jones MD, Mulcahy ND: Osteopathia striata, osteopetrosis, and impaired hearing. A case report. Arch Otolaryngol. 1968, 87 (2): 116-118.View ArticlePubMedGoogle Scholar
- Koudstaal MJ, Wolvius EB, Ongkosuwito EM, van der Wal KG: Surgically assisted rapid maxillary expansion in two cases of osteopathia striata with cranial sclerosis. Cleft Palate Craniofac J. 2008, 45 (3): 337-342.View ArticlePubMedGoogle Scholar
- Lee RD: Clinical images of osteopathia striata. Pediatr Radiol. 2004, 34 (9): 753-View ArticlePubMedGoogle Scholar
- Mohan V, Gupta SK, Bhushan B: Osteopathia striata with cranial sclerosis. Australas Radiol. 1990, 34 (3): 249-252.View ArticlePubMedGoogle Scholar
- Nakamura T, Yokomizo Y, Kanda S, Harada T, Naruse T: Osteopathia striata with cranial sclerosis affecting three family members. Skeletal Radiol. 1985, 14 (4): 267-269.View ArticlePubMedGoogle Scholar
- Odrezin GT, Krasikov N: CT of the temporal bone in a patient with osteopathia striata and cranial sclerosis. AJNR Am J Neuroradiol. 1993, 14 (1): 72-75.PubMedGoogle Scholar
- Paling MR, Hyde I, Dennis NR: Osteopathia striata with sclerosis and thickening of the skull. Br J Radiol. 1981, 54 (640): 344-348.View ArticlePubMedGoogle Scholar
- Pellegrino JE, McDonald-McGinn DM, Schneider A, Markowitz RI, Zackai EH: Further clinical delineation and increased morbidity in males with osteopathia striata with cranial sclerosis: an X-linked disorder?. Am J Med Genet. 1997, 70 (2): 159-165.View ArticlePubMedGoogle Scholar
- Perdu B, de Freitas F, Frints SG, Schouten M, Schrander-Stumpel C, Barbosa M, Pinto-Basto J, Reis-Lima M, de Vernejoul MC, Becker K, Freckmann ML, Keymolen K, Haan E, Savarirayan R, Koenig R, Zabel B, Vanhoenacker FM, Van Hul W: Osteopathia striata with cranial sclerosis due to WTX gene defect. J Bone Miner Res. 2010, 25 (1): 82-90.View ArticlePubMedGoogle Scholar
- Perdu B, Lakeman P, Mortier G, Keonig R, Lachmeijer A, Van HW: Two novel WTX mutations underscore the unpredictability of male survival in osteopathia striata with cranial sclerosis. Clin Genet. 2011, doi:10.1111/j.1399-0004.2010.01553.x. [Epub ahead of print]Google Scholar
- Robinow M, Unger F: Syndrome of osteopathia striata, macrocephaly, and cranial sclerosis. Am J Dis Child. 1984, 138 (9): 821-823.PubMedGoogle Scholar
- Rott HD, Krieg P, Rutschle H, Kraus C: Multiple malformations in a male and maternal osteopathia strata with cranial sclerosis (OSCS). Genet Couns. 2003, 14 (3): 281-288.PubMedGoogle Scholar
- Schnyder PA: Osseous changes of osteopathia striata associated with cranial sclerosis. An autosomal dominant entity. Skeletal Radiol. 1980, 5 (1): 19-22.View ArticlePubMedGoogle Scholar
- Viot G, Lacombe D, David A, Mathieu M, de Broca A, Faivre L, Gigarel N, Munnich A, Lyonnet S, Le Merrer M, Cormier-Daire V: Osteopathia striata cranial sclerosis: non-random X-inactivation suggestive of X-linked dominant inheritance. Am J Med Genet. 2002, 107 (1): 1-4.View ArticlePubMedGoogle Scholar
- Savarirayan R, Nance J, Morris L, Haan E, Couper R: Osteopathia striata with cranial sclerosis: highly variable phenotypic expression within a family. Clin Genet. 1997, 52 (4): 199-205.View ArticlePubMedGoogle Scholar
- Luerssen K, Ptok M: Osteopathia striata with cranial sclerosis and hearing loss. Eur Arch Otorhinolaryngol. 2006, 263 (2): 123-126.View ArticlePubMedGoogle Scholar
- Keymolen K, Bonduelle M, De MM, Liebaers I: How to counsel in osteopathia striata with cranial sclerosis. Genet Couns. 1997, 8 (3): 207-211.PubMedGoogle Scholar
- Barbosa M, Perdu B, Senra V, Macedo F, Van Hul W, Reis-Lima M, Pinto-Basto J: Osteopathia striata with cranial sclerosis. Acta Med Port. 2010, 23 (6): 1147-1150.PubMedGoogle Scholar
- Joseph DJ, Ichikawa S, Econs MJ: Mosaicism in osteopathia striata with cranial sclerosis. J Clin Endocrinol Metab. 2010, 95 (4): 1506-1507.PubMed CentralView ArticlePubMedGoogle Scholar
- Kornreich L, Grunebaum M, Ziv N, Shuper A, Mimouni M: Osteopathia striata, cranial sclerosis with cleft palate and facial nerve palsy. Eur J Pediatr. 1988, 147 (1): 101-103.View ArticlePubMedGoogle Scholar
- Kondoh T, Yoshinaga M, Matsumoto T, Takayanagi T, Uetani M, Kubota T, Nishimura G, Moriuchi H: Severe cervical kyphosis in osteopathia striata with cranial sclerosis: case report. Pediatr Radiol. 2001, 31 (9): 659-662.View ArticlePubMedGoogle Scholar
- Konig R, Dukiet C, Dorries A, Zabel B, Fuchs S: Osteopathia striata with cranial sclerosis: variable expressivity in a four generation pedigree. Am J Med Genet. 1996, 63 (1): 68-73.View ArticlePubMedGoogle Scholar
- Fukuzawa R, Holman SK, Chow CW, Savarirayan R, Reeve AE, Robertson SP: WTX mutations can occur both early and late in the pathogenesis of Wilms tumour. J Med Genet. 2010, 47 (11): 791-794.View ArticlePubMedGoogle Scholar
- Major MB, Camp ND, Berndt JD, Yi X, Goldenberg SJ, Hubbert C, Biechele TL, Gingras AC, Zheng N, Maccoss MJ, Angers S, Moon RT: Wilms tumor suppressor WTX negatively regulates WNT/beta-catenin signaling. Science. 2007, 316 (5827): 1043-1046.View ArticlePubMedGoogle Scholar
- Rivera MN, Kim WJ, Wells J, Stone A, Burger A, Coffman EJ, Zhang J, Haber DA: The tumor suppressor WTX shuttles to the nucleus and modulates WT1 activity. Proc Natl Acad Sci U S A. 2009, 106 (20): 8338-8343.PubMed CentralView ArticlePubMedGoogle Scholar
- Grohmann A, Tanneberger K, Alzner A, Schneikert J, Behrens J: AMER1 regulates the distribution of the tumor suppressor APC between microtubules and the plasma membrane. J Cell Sci. 2007, 120 (Pt 21): 3738-3747.View ArticlePubMedGoogle Scholar
- Huang H, He X: Wnt/beta-catenin signaling: new (and old) players and new insights. Curr Opin Cell Biol. 2008, 20 (2): 119-125.PubMed CentralView ArticlePubMedGoogle Scholar
- Moisan A, Rivera MN, Lotinun S, Akhavanfard S, Coffman EJ, Cook EB, Stoykova S, Mukherjee S, Schoonmaker JA, Burger A, Kim WJ, Kronenberg HM, Baron R, Haber DA, Bardeesy N: The WTX tumor suppressor regulates mesenchymal progenitor cell fate specification. Dev Cell. 2011, 20 (5): 583-596.PubMed CentralView ArticlePubMedGoogle Scholar
- Johnson ML, Rajamannan N: Diseases of Wnt signaling. Rev Endocr Metab Disord. 2006, 7 (1–2): 41-49.PubMed CentralPubMedGoogle Scholar
- Behninger C, Rott HD: Osteopathia striata with cranial sclerosis: literature reappraisal argues for X-linked inheritance. Genet Couns. 2000, 11 (2): 157-167.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.